PSA-gesteuerte Früherkennung des Prostatakarzinoms

[1]  M. Kwiatkowski,et al.  Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland , 2003, BJU international.

[2]  T. H. van der Kwast,et al.  Report of the Pathology Committee: false‐positive and false‐negative diagnoses of prostate cancer , 2003, BJU international.

[3]  M. Roobol,et al.  The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[4]  P. Smith,et al.  The Data Monitoring Committee – bridging the gap between urology and public health epidemiology , 2003, BJU international.

[5]  T. H. van der Kwast,et al.  Consistency of prostate cancer grading results in screened populations across Europe , 2003, BJU international.

[6]  M. Luján,et al.  Four‐year prostate‐specific antigen progression in the non‐cancer population of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[7]  S. Ciatto,et al.  How to improve the specificity and sensitivity of biopsy technique in screening , 2003, BJU international.

[8]  J. Hugosson,et al.  Population‐based screening for prostate cancer by measuring free and total serum prostate‐specific antigen in Sweden , 2003, BJU international.

[9]  J. Coebergh,et al.  ERSPC: features and preliminary results from the Antwerp study centre , 2003, BJU international.

[10]  S. Ciatto,et al.  Specific features of the Italian section of the ERSPC , 2003, BJU international.

[11]  A. Auvinen,et al.  The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening? , 2003, BJU international.

[12]  M. Roobol,et al.  Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) , 2003, BJU international.

[13]  A. Auvinen,et al.  The Finnish trial of prostate cancer screening: where are we now? , 2003, BJU international.

[14]  J. Coebergh,et al.  Determining the cause of death in randomized screening trial(s) for prostate cancer , 2003, BJU International.

[15]  M. Luján,et al.  The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[16]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[17]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. D. de Koning,et al.  Prostate cancer detection at low prostate specific antigen. , 2000, The Journal of urology.

[19]  S. Fosså,et al.  Defining an international research agenda for quality of life in men with prostate cancer , 1999, The Prostate.

[20]  H. D. de Koning,et al.  Advanced prostate cancer: Course, care, and cost implications , 1999, The Prostate.

[21]  F. Schröder,et al.  Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction , 1999, The Prostate.

[22]  P. J. van der Maas,et al.  Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. , 1999, Journal of the National Cancer Institute.

[23]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[24]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.

[25]  J. Hugosson,et al.  Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region) , 1999, The Prostate.

[26]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[27]  F. Labrie,et al.  Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.

[28]  D. Fryback,et al.  Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.

[29]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[30]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[31]  L. Kavoussi,et al.  Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. , 1988, The Journal of urology.

[32]  T. Kwast,et al.  Comparison of pathologic characteristics of T1c and non-Tic cancers detected in a population-based screening study, the European randomized study of screening for prostate cancer , 2005, World Journal of Urology.

[33]  E. Rakovitch,et al.  PSA doubling time of prostate carcinoma managed with watchful observation alone. , 2001, International journal of radiation oncology, biology, physics.

[34]  T. H. van der Kwast,et al.  Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. , 2001, Urology.

[35]  J. Cerhan,et al.  Prostate Cancer Trends 1973-1995, SEER Program National Cancer Institute. , 1999 .

[36]  D L McCullough,et al.  Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. , 1997, The Journal of urology.